+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
DNA Vaccine Market by Application, Technology Platform, Delivery Method, Administration Route, Development Stage, End User - Global Forecast to 2030- Product Image
DNA Vaccine Market by Application, Technology Platform, Delivery Method, Administration Route, Development Stage, End User - Global Forecast to 2030- Product Image
Sale

DNA Vaccine Market by Application, Technology Platform, Delivery Method, Administration Route, Development Stage, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083121
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The DNA Vaccine Market grew from USD 302.54 million in 2024 to USD 344.45 million in 2025. It is expected to continue growing at a CAGR of 13.74%, reaching USD 655.13 million by 2030.

Unlocking the Promise of DNA Vaccines

DNA vaccines have emerged as a pioneering modality that harnesses genetic constructs to induce robust and targeted immune responses against a variety of pathogens and tumor antigens. By delivering plasmid or synthetic DNA sequences encoding disease-specific antigens, these vaccines prompt host cells to express the antigen in situ, stimulating both humoral and cellular immunity without the risk of live pathogen exposure.

This novel platform offers notable advantages over traditional vaccine approaches. It combines a favorable safety profile with rapid scalability, customizable constructs and stability at a wider range of storage conditions. Recent advances in vector optimization, codon usage and adjuvant integration have further enhanced immunogenicity, positioning DNA vaccines as versatile candidates for tackling emerging infectious diseases and oncology indications.

This executive summary delivers a concise synthesis of the current market landscape, recent transformative shifts, regulatory and trade considerations, key segmentation insights, regional dynamics, competitive positioning, actionable recommendations and methodological rigor. It provides decision-makers with clear, evidence-based guidance to navigate the complexities of the DNA vaccine sector and to capitalize on its significant growth potential.

Emerging Dynamics Redefining the DNA Vaccine Market

The DNA vaccine field is undergoing a period of rapid transformation driven by breakthroughs in vector engineering, delivery technologies and regulatory frameworks. Recent technological innovations such as plasmid backbone refinement and incorporation of self-amplifying RNA elements have elevated antigen expression levels and broadened epitope coverage, fostering enhanced immunogenicity profiles.

Simultaneously, progress in non-viral delivery systems-ranging from electroporation devices to nanoparticle carriers-has improved transfection efficiency and patient compliance. Regulatory authorities are responding to these advancements by issuing clearer guidelines on quality control, preclinical safety requirements and clinical trial design, thereby reducing uncertainty and accelerating pathways to market authorization.

Collaborations between academic institutions, biotech innovators and contract development organizations are reshaping the landscape, facilitating the rapid translation of early-stage research into clinical candidates. Moreover, strategic alliances with government agencies and global health initiatives have underscored the importance of DNA vaccines in pandemic preparedness and as part of a diversified immunization toolkit.

Understanding the 2025 US Tariff Implications

The imposition of revised United States tariffs in 2025 on certain biotech raw materials and manufactured vaccine components has introduced both challenges and strategic considerations for stakeholders. Components such as specialized enzymes, nucleotides and carrier particles sourced from key trading partners now face augmented import duties, which can translate into increased production overheads and potential delays in scale-up.

Manufacturers must navigate these new cost pressures by evaluating supply chain reconfigurations, including the identification of alternative domestic suppliers, negotiation of long-term procurement contracts and potential onshoring of critical manufacturing steps. At the same time, trade policy adjustments have prompted greater engagement with customs authorities and industry associations to secure tariff exemptions for research reagents and components deemed essential to public health interventions.

Despite the increased complexity, these tariff measures may also catalyze investment in local manufacturing infrastructure and encourage vertical integration strategies that enhance resilience. Ultimately, the net impact will depend on each organization’s ability to absorb incremental costs, optimize operational efficiency and adapt sourcing strategies to maintain competitive pricing.

Dissecting Market Segments for Strategic Clarity

A nuanced understanding of market segmentation is critical for aligning R&D priorities with unmet clinical needs and commercial objectives. When viewed through the lens of application, the opportunity space spans infectious diseases and oncology, with the former subdividing into bacterial infections, parasitic diseases and viral infections, each presenting distinct immunological challenges. Oncology targets encompass hematological malignancies and solid tumors, where DNA vaccines are being tailored to address tumor-specific antigens and neoepitope profiles.

Examining the technological dimension reveals a tripartite classification of platforms: linear DNA constructs, minicircle DNA vectors and conventional plasmid DNA backbones. Each platform offers a unique balance of payload capacity, expression kinetics and manufacturing complexity. Delivery method segmentation further highlights four principal approaches: electroporation, gene gun delivery, nanoparticle encapsulation and traditional needle injection, each selected based on target tissue, dosage requirements and patient experience.

Administration route analysis underscores the strategic choice among intradermal, intramuscular, intranasal and subcutaneous delivery, which influences immunogenicity profiles and formulation constraints. Development stage segmentation spans preclinical evaluation, Clinical Phase I, Phase II, Phase III and commercial launch, providing insight into the maturity of candidates across therapeutic areas. Finally, end users range from dedicated research institutions to clinics and hospitals, each with distinct procurement processes and adoption drivers.

Regional Variations Shaping DNA Vaccine Adoption

Regional heterogeneity in healthcare infrastructure, regulatory environments and funding ecosystems shapes the adoption of DNA vaccine technologies across the globe. In the Americas, robust clinical pipelines and significant venture capital inflows are driving multiple late-stage candidates toward commercial launch. The well-established regulatory agencies in this region have expedited pathways for novel vaccine modalities under emergency use frameworks and priority review designations.

Europe, the Middle East and Africa present a mosaic of markets characterized by diverse reimbursement schemes, variable manufacturing capabilities and emerging initiatives to bolster local vaccine production. The European Union’s harmonized regulatory network contrasts with localized efforts in the Middle East and North Africa to develop regional biomanufacturing hubs, while sub-Saharan nations prioritize public-private partnerships to improve access to next-generation vaccines.

Asia-Pacific stands out for its expansive manufacturing capacity, government-led immunization programs and growing interest in biotechnology self-sufficiency. Countries within this region are actively investing in GMP facility expansion and incentivizing domestic research collaborations. The convergence of supportive policies and high disease burden forecasts substantial uptake, positioning Asia-Pacific as a key driver of long-term market growth.

Competitive Landscape of Leading DNA Vaccine Innovators

The competitive environment in the DNA vaccine sector is shaped by both established pharmaceutical companies and agile biotechnology firms. Industry leaders are leveraging their global development expertise and extensive manufacturing networks to advance proprietary platforms and secure strategic alliances. These incumbents often focus on late-stage clinical assets with broad applicability across infectious disease and oncology indications.

In parallel, emerging biotech innovators are driving disruptive advances through niche specialization, such as novel plasmid backbone technologies or proprietary nanoparticle formulations. Collaborative models have become prevalent, with many organizations entering co-development or licensing agreements to access complementary capabilities and accelerate time to market. The resulting landscape is one of dynamic interplay between scale, specialization and collaboration, underscoring the importance of strategic positioning and intellectual property management.

Strategic Imperatives for Industry Stakeholders

Industry leaders should prioritize diversification of technological platforms to hedge against single-point failures and capture opportunities across varied therapeutic areas. Investing in modular manufacturing facilities and flexible delivery systems will enable rapid scale-up in response to outbreak scenarios or shifting clinical priorities. Early and proactive engagement with regulatory authorities can streamline approval pathways and inform adaptive trial designs, reducing time to market.

Strengthening supply chain resilience through strategic partnerships with raw material suppliers and fostering regional manufacturing alliances will mitigate the impact of trade policy fluctuations. Collaborations with academic research centers and contract development organizations can augment internal capabilities and facilitate access to emerging scientific breakthroughs. Additionally, integrating real-world evidence and patient-centric outcome measures into clinical development plans can enhance value demonstration for payers and end users.

Finally, maintaining vigilant monitoring of geopolitical trends, tariff developments and evolving reimbursement landscapes will ensure that strategic adjustments can be made swiftly, preserving competitive advantage.

Rigorous Approaches Underpinning Market Insights

The findings presented in this summary are grounded in a robust research methodology combining primary and secondary data sources. Primary research comprised in-depth interviews with senior executives, scientific experts and key opinion leaders across academia, industry and regulatory bodies. These qualitative insights were complemented by quantitative surveys targeting R&D managers, manufacturing directors and procurement specialists to validate market assumptions.

Secondary research involved systematic analysis of peer-reviewed literature, corporate filings, patent databases and clinical trial registries, providing a comprehensive view of technological advancements, pipeline progress and competitive activity. Data triangulation techniques were applied to reconcile discrepancies and enhance accuracy, while an internal expert panel conducted iterative reviews to ensure consistency and relevance.

This multi-layered approach delivers a high degree of confidence in the insights presented, offering stakeholders a reliable foundation for strategic planning, investment decisions and partnership exploration.

Synthesis of Key Findings and Future Outlook

This executive summary has illuminated the transformative potential of DNA vaccine technology, underscored by recent platform innovations, evolving regulatory landscapes and the nuanced implications of US tariff measures. Key segmentation analysis has revealed strategic pathways across applications, platforms, delivery methods, administration routes, development stages and end users, while regional insights have highlighted the Americas, Europe, Middle East & Africa and Asia-Pacific as pivotal growth engines.

Competitive dynamics are shaped by established industry titans and nimble biotech challengers, with strategic collaborations and platform diversification emerging as critical success factors. Actionable recommendations emphasize flexible manufacturing, regulatory alignment, supply chain resilience and integrated real-world evidence strategies. The meticulous methodology employed ensures that these conclusions rest on a solid foundation of expert perspectives and comprehensive data analysis.

Looking ahead, the DNA vaccine market is poised for accelerated expansion, driven by its adaptability to emerging health threats and potential applications beyond traditional prophylactic vaccines. Stakeholders who leverage these insights to anticipate market shifts and optimize their strategic positioning will be best placed to capitalize on the opportunities this dynamic field presents.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Infectious Diseases
      • Bacterial Infections
      • Parasitic Diseases
      • Viral Infections
    • Oncology
      • Hematological Malignancies
      • Solid Tumors
  • Technology Platform
    • Linear DNA
    • Minicircle DNA
    • Plasmid DNA
  • Delivery Method
    • Electroporation
    • Gene Gun
    • Nanoparticle Delivery
    • Needle Injection
  • Administration Route
    • Intradermal
    • Intramuscular
    • Intranasal
    • Subcutaneous
  • Development Stage
    • Clinical Phase I
    • Clinical Phase II
    • Clinical Phase III
    • Commercial
    • Preclinical
  • End User
    • Clinics
    • Hospitals
    • Research Institutions
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Inovio Pharmaceuticals, Inc.
  • GeneOne Life Science, Inc.
  • VGXI, Inc.
  • Zydus Cadila Ltd.
  • GenScript Biotech Corporation
  • Applied DNA Sciences, Inc.
  • Entos Pharmaceuticals, Inc.
  • Takis Biotech S.r.l.
  • Vical, Inc.
  • Merck & Co., Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Transformative Progress and Current Significance of the DNA Vaccine Market
3.2. Driving Forces, Strategic Approaches, and Regulatory Nuances in Consumer Adoption
3.3. Lifecycle Dynamics, Intellectual Property Insights, and Strategic Market Entry
3.4. Forward-Looking Market Prospects, Growth Strategies, and Technological Innovations
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. DNA Vaccine Market, by Application
8.1. Introduction
8.2. Infectious Diseases
8.2.1. Bacterial Infections
8.2.2. Parasitic Diseases
8.2.3. Viral Infections
8.3. Oncology
8.3.1. Hematological Malignancies
8.3.2. Solid Tumors
9. DNA Vaccine Market, by Technology Platform
9.1. Introduction
9.2. Linear DNA
9.3. Minicircle DNA
9.4. Plasmid DNA
10. DNA Vaccine Market, by Delivery Method
10.1. Introduction
10.2. Electroporation
10.3. Gene Gun
10.4. Nanoparticle Delivery
10.5. Needle Injection
11. DNA Vaccine Market, by Administration Route
11.1. Introduction
11.2. Intradermal
11.3. Intramuscular
11.4. Intranasal
11.5. Subcutaneous
12. DNA Vaccine Market, by Development Stage
12.1. Introduction
12.2. Clinical Phase I
12.3. Clinical Phase II
12.4. Clinical Phase III
12.5. Commercial
12.6. Preclinical
13. DNA Vaccine Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Hospitals
13.4. Research Institutions
14. Americas DNA Vaccine Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa DNA Vaccine Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific DNA Vaccine Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Inovio Pharmaceuticals, Inc.
17.3.2. GeneOne Life Science, Inc.
17.3.3. VGXI, Inc.
17.3.4. Zydus Cadila Ltd.
17.3.5. GenScript Biotech Corporation
17.3.6. Applied DNA Sciences, Inc.
17.3.7. Entos Pharmaceuticals, Inc.
17.3.8. Takis Biotech S.r.l.
17.3.9. Vical, Inc.
17.3.10. Merck & Co., Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DNA VACCINE MARKET MULTI-CURRENCY
FIGURE 2. DNA VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. DNA VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DNA VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DNA VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 60. CANADA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 61. CANADA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 62. CANADA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 63. CANADA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 64. CANADA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 65. CANADA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 68. MEXICO DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 69. MEXICO DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 70. MEXICO DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 71. MEXICO DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 109. GERMANY DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 110. GERMANY DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 111. GERMANY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 112. GERMANY DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 113. GERMANY DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 114. GERMANY DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 117. FRANCE DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 118. FRANCE DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 119. FRANCE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 120. FRANCE DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 121. FRANCE DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 133. ITALY DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 134. ITALY DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 135. ITALY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 136. ITALY DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 137. ITALY DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 138. ITALY DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 141. SPAIN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 142. SPAIN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 143. SPAIN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 144. SPAIN DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 145. SPAIN DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 146. SPAIN DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 173. DENMARK DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 174. DENMARK DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 175. DENMARK DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 176. DENMARK DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 177. DENMARK DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 178. DENMARK DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 189. QATAR DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 190. QATAR DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 191. QATAR DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 192. QATAR DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 193. QATAR DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 194. QATAR DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 197. FINLAND DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 198. FINLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 199. FINLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 200. FINLAND DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 201. FINLAND DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 202. FINLAND DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 221. EGYPT DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 222. EGYPT DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 223. EGYPT DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 224. EGYPT DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 225. EGYPT DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 226. EGYPT DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 229. TURKEY DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 230. TURKEY DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 231. TURKEY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 232. TURKEY DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 233. TURKEY DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 234. TURKEY DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 245. NORWAY DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 246. NORWAY DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 247. NORWAY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 248. NORWAY DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 249. NORWAY DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 250. NORWAY DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 253. POLAND DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 254. POLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 255. POLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 256. POLAND DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 257. POLAND DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 258. POLAND DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 276. CHINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. CHINA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 278. CHINA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 279. CHINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 280. CHINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 281. CHINA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 282. CHINA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 283. CHINA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. INDIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. INDIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 286. INDIA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 287. INDIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 288. INDIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 289. INDIA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 290. INDIA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 291. INDIA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. JAPAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 294. JAPAN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 295. JAPAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 296. JAPAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 297. JAPAN DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 298. JAPAN DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 299. JAPAN DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. THAILAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 325. THAILAND DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 326. THAILAND DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 327. THAILAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 328. THAILAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 329. THAILAND DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 330. THAILAND DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 331. THAILAND DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 338. PHILIPPINES DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 339. PHILIPPINES DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 345. MALAYSIA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 346. MALAYSIA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 347. MALAYSIA DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 349. SINGAPORE DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 350. SINGAPORE DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 351. SINGAPORE DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 352. SINGAPORE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 353. SINGAPORE DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 354. SINGAPORE DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 355. SINGAPORE DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 356. VIETNAM DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 357. VIETNAM DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 358. VIETNAM DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 359. VIETNAM DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 360. VIETNAM DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 361. VIETNAM DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 362. VIETNAM DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 363. VIETNAM DNA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 364. TAIWAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 365. TAIWAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 366. TAIWAN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 367. TAIWAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 368. TAIWAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD,

Companies Mentioned

The companies profiled in this DNA Vaccine market report include:
  • Inovio Pharmaceuticals, Inc.
  • GeneOne Life Science, Inc.
  • VGXI, Inc.
  • Zydus Cadila Ltd.
  • GenScript Biotech Corporation
  • Applied DNA Sciences, Inc.
  • Entos Pharmaceuticals, Inc.
  • Takis Biotech S.r.l.
  • Vical, Inc.
  • Merck & Co., Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 344.45 Million
Forecasted Market Value ( USD ) by 2030 $ 655.13 Million
Compound Annual Growth Rate13.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Human DNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Human DNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
DNA Vaccines - Global Strategic Business Report - Product Image

DNA Vaccines - Global Strategic Business Report

  • Report
  • 171 Pages
  • Global
From
Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Vaccine Contract Manufacturing - Global Strategic Business Report - Product Image

Vaccine Contract Manufacturing - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From

About the DNA Vaccines Market

DNA vaccines are a type of genomics-based vaccine that uses genetic material from a virus or bacteria to stimulate an immune response. They are created by introducing a gene that codes for a specific antigen into a plasmid, which is then inserted into a host cell. The host cell then produces the antigen, which is then used to stimulate an immune response. DNA vaccines are considered to be safer than traditional vaccines, as they do not contain any live virus or bacteria. Additionally, they can be produced more quickly and cheaply than traditional vaccines. DNA vaccines have been used to treat a variety of diseases, including influenza, malaria, and HIV. They have also been used to develop vaccines for cancer and other diseases. Recently, DNA vaccines have been used to develop vaccines for the prevention of infectious diseases, such as Zika virus and Ebola. Companies in the DNA Vaccines market include Moderna, Inovio Pharmaceuticals, Novavax, and Transgene. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.